Haiqin Huang

Dr. Haiqin Huang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Drug Delivery
Verified
Journal Article
Open access
PJPeng Ji
Peng Ji
XWXianglong Wang
Xianglong Wang
JYJiabing Yin
Jiabing Yin
YMYi Mou
Yi Mou
HHHaiqin Huang
Haiqin Huang
ARAnd Zhenkun Ren
And Zhenkun Ren
Breast cancer is prevalent and diverse with significantly high incidence and mortality rates. Curcumin (Cur), a polyphenol component of turmeric, has been widely recognized as having strong anti-breast cancer activity. However, its anti-cancer efficiency is largely impaired by some of its concomitant negative properties, including its poor solubility, low cellular uptake, and severe reported side effects. Hence, the necessity arises to develop a novel low-toxic and high-efficiency targeting drug delivery system (DDS). In this study, we developed a pH-sensitive tumor self-targeting DDS (Cur@HFn) based on self-assembled HFn loaded with Cur, in which Cur was encapsulated into HFn cavity by using a disassembly/reassembly strategy, and the Cur@HFn was characterized by ultraviolet–visible (UV–vis), dynamic light scattering (DLS), and transmission electron microscope (TEM). A variety of breast cancer cell models were built to evaluate cytotoxicity, apoptosis, targeting properties, and uptake mechanism of the Cur@HFn. The pharmacodynamics was also evaluated in tumor (4T1) bearing mice after intravenous injection. In vitro release experiments showed that Cur@HFn is pH sensitive and shows sustained drug release under slightly acidic conditions. Compared with Cur, Cur@HFn has stronger cytotoxicity, cellular uptake, and targeting performance. Our study supported that Cur@HFn has a higher in vivo therapeutic effect and lower systemic toxicity. The safety evaluation results indicated that Cur@HFn has no hematotoxicity, hepatotoxicity, and nephrotoxicity. The findings of the present study showed that the Cur@HFn has been successfully prepared and has potential application value in the treatment of breast cancer.

11 January 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LXLixing Xu
Lixing Xu
EBEnhe Bai
Enhe Bai
YZYangbo Zhu
Yangbo Zhu
JQJiayi Qin
Jiayi Qin
XDXiao Du
Xiao Du
HHHaiqin Huang
Haiqin Huang
Gastric ulcer is one of the most common gastrointestinal diseases, and natural products have obvious advantages in the treatment of gastrointestinal diseases. Baicalin (Bai) extracted from scutellaria baicalensis exhibits anti-inflammatory, antioxidant, and anti-apoptotic activities. Herein, a pH-responsive sodium alginate/polyaspartate/CaCO3 (SA/PASP@CaCO3) in situ hydrogel was established for the oral delivery of Bai. In this study, we detected the gelling properties, mechanical strength, in vitro erosion, and in vitro release behavior of the hydrogels. Meanwhile, the efficiency of Bai/SA/PASP@CaCO3 hydrogel on ethanol-induced acute gastric ulcers, acetic acid-induced chronic gastric ulcers, and H2O2-stimulated human gastric epithelial GES-1 cells was explored. The pathological examination revealed that Bai-loaded hydrogel alleviated acute and chronic gastric ulcers. In vivo and in vitro results further confirmed that Bai/SA/PASP@CaCO3 in situ hydrogels significantly relieved oxidative stress injury. Moreover, through Western blot assay, Bai/SA/PASP@CaCO3 hydrogel was also found to dramatically increase the proteins levels of NRF2, HO-1, and Bcl2, and reduce levels of p-JNK, cleaved-caspase-3 and Bax; through flow cytometry, it was observed to significantly inhibit the H2O2-induced apoptosis of GES-1 cells. Importantly, the Bai/SA/PASP@CaCO3 in situ hydrogel system showed better anti-gastric ulcer efficiency than free drug, and could serve as a potential drug delivery system for the clinical treatment of gastric ulcers.

14 March 2023 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LXLixing Xu
Lixing Xu
XDXiao Du
Xiao Du
YZYao Zhou
Yao Zhou
XCXinyu Cao
Xinyu Cao
YSYing Shen
Ying Shen
HHHaiqin Huang
Haiqin Huang

16 March 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KCKeyue Cao
Keyue Cao
YZYao Zhou
Yao Zhou
YSYing Shen
Ying Shen
YWYifei Wang
Yifei Wang
HHHaiqin Huang
Haiqin Huang
HZHongyan Zhu
Hongyan Zhu

12 March 2024 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DSDan Sun
Dan Sun
XDXiao Du
Xiao Du
XCXinyu Cao
Xinyu Cao
BWBingyu Wu
Bingyu Wu
SLShanshan Li
Shanshan Li
HHHaiqin Huang
Haiqin Huang

27 January 2025 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
XCXinyu Cao
Xinyu Cao
SWShen Wan
Shen Wan
BWBingyu Wu
Bingyu Wu
ZLZhikuan Liu
Zhikuan Liu
LXLixing Xu
Lixing Xu
HHHaiqin Huang
Haiqin Huang